Copiktra Alternatives Compared
| Copiktra (duvelisib) | Jaypirca (pirtobrutinib) | Imbruvica (ibrutinib) |
|
|---|
| Copiktra (duvelisib) | Jaypirca (pirtobrutinib) | Imbruvica (ibrutinib) |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Chronic Lymphocytic Leukemia. Copiktra may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma. Jaypirca may also be used for purposes not listed in this medication guide. |
Prescription only
Imbruvica is an oral tablet that may be taken once daily to treat certain types of cancers in adults or to treat chronic Graft Versus Host disease in adults and children older than 1 year. It works... View more |
||||||||||||||||||||||||
| More about Copiktra (duvelisib) | More about Jaypirca (pirtobrutinib) | More about Imbruvica (ibrutinib) | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Be the first to share your experience with this drug. |
Jaypirca has an average rating of 8.8 out of 10 from a total of 4 ratings on Drugs.com. 75% of reviewers reported a positive effect, while 0% reported a negative effect. |
Imbruvica has an average rating of 6.5 out of 10 from a total of 65 ratings on Drugs.com. 59% of reviewers reported a positive effect, while 31% reported a negative effect. |
||||||||||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||||||||||
|
View all Copiktra side effects |
View all Jaypirca side effects |
View all Imbruvica side effects |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Copiktra prices |
View all Jaypirca prices |
View all Imbruvica prices |
||||||||||||||||||||||||
| Dosage Forms | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||||||||||
|
4.7 hours |
19 hours |
6 hours |
||||||||||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 623 drugs are known to interact with Copiktra:
|
A total of 722 drugs are known to interact with Jaypirca:
|
A total of 495 drugs are known to interact with Imbruvica:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
September 24, 2018 |
January 27, 2023 |
November 13, 2013 |
||||||||||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient Resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.